BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

568 related articles for article (PubMed ID: 19287335)

  • 1. Comparison between mucinous cystic neoplasm and intraductal papillary mucinous neoplasm of the branch duct type of the pancreas with respect to expression of CD10 and cytokeratin 20.
    Nishigami T; Onodera M; Torii I; Sato A; Tao LH; Kushima R; Kakuno A; Kishimoto M; Katsuyama E; Fujimori T; Hirano H; Satake M; Kuroda N; Nishiguchi S; Fujimoto J; Tsujimura T
    Pancreas; 2009 Jul; 38(5):558-64. PubMed ID: 19287335
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Human pancreatic mucinous cystadenoma is characterized by distinct mucin, cytokeratin and CD10 expression compared with intraductal papillary-mucinous adenoma.
    Handra-Luca A; Fléjou JF; Rufat P; Corcos O; Belghiti J; Ruszniewski P; Degott C; Bedossa P; Couvelard A
    Histopathology; 2006 Jun; 48(7):813-21. PubMed ID: 16722930
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Diagnosis and differential diagnosis of intraductal papillary mucinous neoplasm of pancreas].
    Ji Y; Tan YS; Zhu XZ; Zeng HY; Kuang TT; Jin DY
    Zhonghua Bing Li Xue Za Zhi; 2006 Feb; 35(2):77-81. PubMed ID: 16630480
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The expression of several types of mucin is related to the biological behavior of pancreatic neoplasms.
    Yonezawa S; Nakamura A; Horinouchi M; Sato E
    J Hepatobiliary Pancreat Surg; 2002; 9(3):328-41. PubMed ID: 12353144
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mucin gene expression in intraductal papillary-mucinous pancreatic tumours and related lesions.
    Terris B; Dubois S; Buisine MP; Sauvanet A; Ruszniewski P; Aubert JP; Porchet N; Couvelard A; Degott C; Fléjou JF
    J Pathol; 2002 Aug; 197(5):632-7. PubMed ID: 12210083
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intraductal papillary mucinous neoplasm (IPMN) of the pancreas: its histopathologic difference between 2 major types.
    Ban S; Naitoh Y; Mino-Kenudson M; Sakurai T; Kuroda M; Koyama I; Lauwers GY; Shimizu M
    Am J Surg Pathol; 2006 Dec; 30(12):1561-9. PubMed ID: 17122512
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MUC2 expression and prevalence of high-grade dysplasia and invasive carcinoma in mixed-type intraductal papillary mucinous neoplasm of the pancreas.
    Masuda A; Arisaka Y; Hara S; Matsumoto I; Takenaka M; Sakai A; Shiomi H; Matsuki N; Sugimoto M; Fujita T; Hayakumo T; Ku Y; Ogino S; Azuma T; Kutsumi H
    Pancreatology; 2013; 13(6):583-8. PubMed ID: 24280573
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Frequency of subtypes of biliary intraductal papillary mucinous neoplasm and their MUC1, MUC2, and DPC4 expression patterns differ from pancreatic intraductal papillary mucinous neoplasm.
    Sclabas GM; Barton JG; Smyrk TC; Barrett DA; Khan S; Kendrick ML; Reid-Lombardo KM; Donohue JH; Nagorney DM; Que FG
    J Am Coll Surg; 2012 Jan; 214(1):27-32. PubMed ID: 22112419
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intraductal papillary mucinous neoplasm of the pancreas: cytologic features predict histologic grade.
    Michaels PJ; Brachtel EF; Bounds BC; Brugge WR; Pitman MB
    Cancer; 2006 Jun; 108(3):163-73. PubMed ID: 16550572
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characteristic clinicopathological features of the types of intraductal papillary-mucinous neoplasms of the pancreas.
    Ishida M; Egawa S; Aoki T; Sakata N; Mikami Y; Motoi F; Abe T; Fukuyama S; Sunamura M; Unno M; Moriya T; Horii A; Furukawa T
    Pancreas; 2007 Nov; 35(4):348-52. PubMed ID: 18090241
    [TBL] [Abstract][Full Text] [Related]  

  • 11. S100P is a novel marker to identify intraductal papillary mucinous neoplasms.
    Nakata K; Nagai E; Ohuchida K; Hayashi A; Miyasaka Y; Aishima S; Oda Y; Mizumoto K; Tanaka M; Tsuneyoshi M
    Hum Pathol; 2010 Jun; 41(6):824-31. PubMed ID: 20153506
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunohistochemical analysis of claudin expression in pancreatic cystic tumors.
    Lee JH; Kim KS; Kim TJ; Hong SP; Song SY; Chung JB; Park SW
    Oncol Rep; 2011 Apr; 25(4):971-8. PubMed ID: 21206985
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The dichotomy in the preinvasive neoplasia to invasive carcinoma sequence in the pancreas: differential expression of MUC1 and MUC2 supports the existence of two separate pathways of carcinogenesis.
    Adsay NV; Merati K; Andea A; Sarkar F; Hruban RH; Wilentz RE; Goggins M; Iocobuzio-Donahue C; Longnecker DS; Klimstra DS
    Mod Pathol; 2002 Oct; 15(10):1087-95. PubMed ID: 12379756
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High expression of intestinal-type mucin (MUC2) in intraductal papillary mucinous neoplasms coexisting with extrapancreatic gastrointestinal cancers.
    Lee SY; Choi DW; Jang KT; Lee KT; Choi SH; Heo JS; Lee JK; Paik SW; Rhee JC
    Pancreas; 2006 Mar; 32(2):186-9. PubMed ID: 16552339
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New classification of pancreatic intraductal papillary-mucinous tumour by mucin expression: its relationship with potential for malignancy.
    Nakamura A; Horinouchi M; Goto M; Nagata K; Sakoda K; Takao S; Imai K; Kim YS; Sato E; Yonezawa S
    J Pathol; 2002 Jun; 197(2):201-10. PubMed ID: 12015744
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of histologic subtype and growth pattern in intraductal papillary-mucinous carcinoma of the pancreas.
    Sanada Y; Kunita S; Yoshida K
    Oncol Rep; 2008 Jun; 19(6):1435-43. PubMed ID: 18497948
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Management of intraductal papillary-mucinous neoplasm of the pancreas: treatment strategy based on morphologic classification.
    Serikawa M; Sasaki T; Fujimoto Y; Kuwahara K; Chayama K
    J Clin Gastroenterol; 2006 Oct; 40(9):856-62. PubMed ID: 17016145
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Clinical and morphological characteristics of intraductal papillary mucinous tumors of the pancreas].
    Dubova EA; Shchegolev AI
    Arkh Patol; 2009; 71(2):9-12. PubMed ID: 19507570
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MUC1 overexpression is the most reliable marker of invasive carcinoma in intraductal papillary-mucinous tumor (IPMT).
    Ueda M; Miura Y; Kunihiro O; Ishikawa T; Ichikawa Y; Endo I; Sekido H; Togo S; Shimada H
    Hepatogastroenterology; 2005; 52(62):398-403. PubMed ID: 15816444
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination of MUC5ac and WT-1 immunohistochemistry is useful in distinguishing pancreatic ductal carcinoma from ovarian serous carcinoma in effusion cytology.
    Han L; Pansare V; Al-Abbadi M; Husain M; Feng J
    Diagn Cytopathol; 2010 May; 38(5):333-6. PubMed ID: 19856421
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.